At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
combined TAS-102 and TAS-OXdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TAS-102 and Oxaliplatin (TAS-OX) for Refractory Metastatic Colon Cancer
In Brief
A Phase 2 clinical trial evaluating combined TAS-102 and TAS-OX for Colorectal Neoplasms. Completed, enrolled 41 participants across 1 site.
Detailed Summary
This study will examine the safety and effectiveness of oxaliplatin in combination with TAS-102 (TAS-OX) for treatment of patients with metastatic colorectal cancer whose cancer has progressed or recurred after FOLFOX chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Neoplasms
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartOct 2016
Primary CompletionJun 2020
TodayJul 2026
First PostedJul 28, 2016
Enrollment StartOct 31, 2016
Primary CompletionJun 2, 2020
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.9 years ago
Interventions
combined TAS-102 and TAS-OXdrug
Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.